The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients
Authors:
Open Access
- 1 July 1998
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 12 (7) , 657-665
Abstract
Background: Intravenous octreotide is an established treatment of oesophageal variceal haemorrhage in the cirrhotic patient. Aim: To examine the organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients with portal hypertension. Methods: Thirteen patients with cirrhosis had hepatic venous catheterization performed. Hepatic venous pressure gradient (HVPG), indocyanine green (ICG) clearance and hepatic blood flow (HBF) were determined in the basal state and during 60 min of octreotide infusion by bolus injection (0.75 μg/kg) followed by continuous infusion of 0.75 μg/kg.h. Blood samples were simultaneously drawn from the femoral artery and the hepatic and renal veins. Results: The extraction fraction of octreotide in the liver was 0.05 (− 0.01–0.14) (median (interquartile range)) and in the kidneys 0.16 (− 0.06–0.35). The extraction fraction ratio (Eliver/Ekidney) was 0.69 (− 0.20–1.06). Hepatic clearance was 47 mL/min (3–88) (n = 11). No correlations were found between liver biochemistry or galactose elimination capacity (GEC; a metabolic measure of liver function) and renal extraction fraction or liver clearance. Octreotide had no effect on HVPG or wedged hepatic venous pressure although free hepatic venous pressure increased during octreotide infusion: 6 mmHg (5–9) vs. 7 mmHg (6–10) (P = 0.02). No effect on HBF was observed while ICG clearance decreased significantly. Conclusions: Octreotide is extracted in cirrhotic patients by both the liver and the kidney, the latter being the most important organ of elimination. Octreotide decreases liver metabolic activity determined by the ICG clearance technique, but no significant effects of octreotide on HVPG or HBF could be demonstrated.Keywords
This publication has 41 references indexed in Scilit:
- Short‐ and long‐term hemodynamic response to octreotide in portal hypertensive patients: a double‐blind, controlled studyLiver International, 1996
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver DiseaseClinical Pharmacokinetics, 1995
- Effects of High Dose Atrial Natriuretic Peptide on Renal Haemodynamics, Sodium Handling and Hormones in Cirrhotic Patients with and Without AscitesScandinavian Journal of Clinical and Laboratory Investigation, 1995
- Assessment of Liver Metabolic FunctionClinical Pharmacokinetics, 1994
- Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertensionJournal of Hepatology, 1994
- Biliary ExcretionThe Journal of Clinical Pharmacology, 1987
- Hepatic blood flow determinationJournal of Hepatology, 1987
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973
- Determination of Hepatic Blood Flow in Man by Cardio GreenScandinavian Journal of Clinical and Laboratory Investigation, 1960